KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Long-Term Deferred Tax (2016 - 2025)

Historic Long-Term Deferred Tax for Regeneron Pharmaceuticals (REGN) over the last 15 years, with Q4 2025 value amounting to $4.1 billion.

  • Regeneron Pharmaceuticals' Long-Term Deferred Tax rose 2302.59% to $4.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.1 billion, marking a year-over-year increase of 2302.59%. This contributed to the annual value of $4.1 billion for FY2025, which is 2302.59% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Long-Term Deferred Tax of $4.1 billion as of Q4 2025, which was up 2302.59% from $3.8 billion recorded in Q3 2025.
  • Regeneron Pharmaceuticals' 5-year Long-Term Deferred Tax high stood at $4.1 billion for Q4 2025, and its period low was $723.2 million during Q3 2021.
  • Over the past 5 years, Regeneron Pharmaceuticals' median Long-Term Deferred Tax value was $2.2 billion (recorded in 2023), while the average stood at $2.2 billion.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first tumbled by 1007.21% in 2021, then skyrocketed by 10078.82% in 2022.
  • Over the past 5 years, Regeneron Pharmaceuticals' Long-Term Deferred Tax (Quarter) stood at $876.9 million in 2021, then surged by 96.57% to $1.7 billion in 2022, then surged by 49.41% to $2.6 billion in 2023, then rose by 28.68% to $3.3 billion in 2024, then rose by 23.03% to $4.1 billion in 2025.
  • Its last three reported values are $4.1 billion in Q4 2025, $3.8 billion for Q3 2025, and $3.6 billion during Q2 2025.